Nanoscope moves mutation-agnostic MOGENRY gene therapy into FDA review

The United States Food and Drug Administration (FDA) has accepted and filed Nanoscope Therapeutics’ Biologics License Application (BLA) for MOGENRY, or sonpiretigene isteparvovec, an optogenetic gene therapy intended to restore vision in people with retinitis pigmentosa and severe vision loss. If approved, Nanoscope says MOGENRY could become the first gene-agnostic treatment for this patient population, meaning eligibility would not depend on identifying one specific disease-causing mutation. The BLA is supported by the randomized RESTORE study, earlier Phase 1/2a data and longer-term REMAIN follow-up.

MOGENRY uses an AAV2 vector to deliver a multi-characteristic opsin to surviving retinal bipolar cells, effectively attempting to make those cells light-sensitive after photoreceptors have degenerated. That mechanism is fundamentally different from gene-replacement approaches designed to correct one defective inherited gene.

Why could mutation-agnostic treatment materially expand access in retinitis pigmentosa?

Retinitis pigmentosa is not one genetic disease. It is a group of inherited retinal disorders caused by many different mutations that eventually damage photoreceptors and progressively reduce vision.

Gene-specific treatment requires identifying the relevant mutation and developing a therapy capable of addressing that particular defect. That can work exceptionally well for selected patients but leaves large genetically heterogeneous populations without a treatment matched to their mutation.

MOGENRY takes a downstream approach. Instead of repairing the mutation responsible for photoreceptor loss, it attempts to use surviving bipolar cells in the retina to restore sensitivity to light after photoreceptors have already been severely damaged.

That architecture can potentially make one product relevant across multiple genetic causes of RP. Nanoscope also describes the treatment as a single in-office intravitreal injection that does not require genetic testing or retinal surgery, potentially simplifying delivery compared with more invasive retinal gene-therapy procedures.

The FDA review will determine whether the evidence generated in a small rare-disease programme is sufficiently convincing to support that broad therapeutic proposition.

How strong was the randomized RESTORE evidence behind the BLA?

RESTORE enrolled 27 patients, with 18 receiving MCO-010 and nine receiving sham treatment. The programme therefore generated randomized evidence, but the sample is very small compared with pivotal trials in common diseases.

At week 52, the high-dose group achieved a mean best-corrected visual acuity improvement of approximately 0.337 LogMAR, while the low-dose group improved by approximately 0.382 LogMAR, with both comparisons reaching statistical significance versus sham. At week 76, the high-dose group improved by approximately 0.539 LogMAR and remained statistically significant, while the low-dose comparison no longer reached statistical significance at that time point.

Seven of 18 treated participants had at least a three-line-equivalent visual acuity improvement at week 52, rising to ten of 18 by week 76. The programme also reported functional-vision improvements on mobility and object-recognition measures.

The strength is that Nanoscope produced randomized controlled evidence in an extremely difficult severe-vision-loss population. The weakness is sample size, which makes durability, consistency and safety follow-up particularly important to the regulatory assessment.

Why does the three-year REMAIN follow-up matter so much for a one-time therapy?

Gene therapies are designed to produce durable biological effects after a single administration, making persistence of benefit central to the value proposition. A strong response at one year becomes less compelling if it fades rapidly afterward.

Nanoscope reported that participants followed through REMAIN maintained an average best-corrected visual-acuity gain of approximately 0.3 LogMAR, equivalent to roughly three lines or 15 letters on a standard chart, through 152 weeks. The company also reported a favorable long-term safety profile.

Those data strengthen the case that MOGENRY’s mechanism continues functioning after the initial treatment period. Long-term durability could also make a one-time therapy economically attractive relative to chronic treatment if regulators and payers accept the evidence.

Safety remains especially important because the treatment permanently introduces genetic material into retinal cells. Earlier RESTORE data showed no serious treatment-related events, although anterior-chamber inflammation and ocular hypertension occurred more frequently in treated patients and were managed with topical medication.

FDA review will therefore involve both whether patients gained meaningful vision and whether the risk profile is acceptable for a treatment intended to produce long-lasting changes after one injection.

How could MOGENRY change the economics of retinal gene therapy if approved?

A mutation-agnostic treatment could address a broader commercial population than therapies limited to one rare genotype. Nanoscope would still be treating a severe, uncommon retinal disease, but it would not need separate products for every genetic subgroup.

Office-based intravitreal administration may also influence economics. Retina specialists already perform intravitreal injections routinely, meaning the delivery infrastructure could fit more naturally into existing ophthalmology practice than procedures requiring specialized retinal surgery.

Manufacturing remains more complex than producing conventional injected drugs because MOGENRY is an AAV-based biological therapy. Nanoscope has expanded its relationship with Catalent to support late-phase and commercial supply, indicating that manufacturing scale is already part of its commercialization planning.

Pricing has not been disclosed, and an approved one-time gene therapy could face intense payer scrutiny. Commercial success would depend on demonstrating that restored vision creates durable patient benefit sufficient to justify the treatment’s eventual price.

The BLA acceptance is therefore an inflection point but not the end of development risk. Manufacturing inspection, labeling, regulatory questions and final approval still remain ahead.

Could the same optogenetic platform extend beyond retinitis pigmentosa?

Nanoscope is already studying the approach in other retinal degenerative diseases. Its platform is being explored in Stargardt disease and geographic atrophy, while the company has also conducted preclinical work suggesting potential use across other conditions involving photoreceptor degeneration.

That platform opportunity could become substantially more valuable if MOGENRY receives the first regulatory approval. Commercial manufacturing, regulatory precedent and physician familiarity established in RP could lower development barriers for follow-on indications.

The biology still has to work separately in each disease. Retinitis pigmentosa, Stargardt disease and geographic atrophy have different natural histories, patient populations and retinal characteristics.

The FDA’s review of MOGENRY is consequently important beyond one rare disease. Approval could validate the broader concept of mutation-independent optogenetic vision restoration using remaining retinal circuitry.

What are the biggest remaining questions during FDA review?

The first is whether a 27-person randomized trial, supported by earlier and longer-term data, provides sufficiently robust evidence for approval. Rare diseases can justify smaller studies, but regulators still need confidence that the observed benefit is real and clinically meaningful.

The second is durability and safety. REMAIN provides encouraging three-year follow-up, but gene therapies require careful long-term monitoring because treatment cannot simply be stopped after administration.

Manufacturing consistency is another critical issue. A commercial AAV product must be produced repeatedly with controlled potency, purity and quality.

Finally, the exact approved population matters. Label language determining disease severity, patient eligibility and other clinical criteria will directly affect commercial opportunity.

Nanoscope has crossed from filing-stage biotech into active regulatory review. The next milestone is no longer another exploratory dataset. It is whether the FDA considers the complete evidence sufficient to put MOGENRY into retina clinics.

Key takeaways on Nanoscope Therapeutics’ MOGENRY BLA

• FDA has accepted and filed the MOGENRY BLA.
• MOGENRY is also known as sonpiretigene isteparvovec or MCO-010.
• It is being reviewed for RP patients with severe vision loss.
• The therapy is designed to work regardless of the underlying gene mutation.
• Treatment consists of a one-time intravitreal injection.
• RESTORE enrolled 27 patients.
• Both treatment doses met the week-52 visual-acuity endpoint.
• Three-year follow-up showed an average approximately three-line vision gain from baseline.
• MOGENRY uses an AAV2 optogenetic approach targeting surviving bipolar retinal cells.
• Regulatory approval, manufacturing review and eventual labeling are now the major milestones.